About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altamira Therapeutics Ltd (NQ: CYTO )

1.160 +0.080 (+7.41%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 106,602
Open 1.100
Bid (Size) 1.130 (6)
Ask (Size) 1.220 (14)
Prev. Close 1.080
Today's Range 1.080 - 1.200
52wk Range 0.9960 - 17.20
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
From Altamira Therapeutics Ltd
Via GlobeNewswire

Performance

YTD
-66.47%
-66.47%
1 Month
-1.69%
-1.69%
3 Month
-19.44%
-19.44%
6 Month
-49.12%
-49.12%
1 Year
-82.21%
-82.21%

More News

Read More
Altamira Therapeutics Provides Business Update
From Altamira Therapeutics Ltd
Via GlobeNewswire
Hunting For Gains In Penny Stocks
Via Talk Markets
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
Via FinancialNewsMedia
Topics Death
Exposures Death
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With Altamira Therapeutics Stock?
Via Benzinga
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032
From FN Media Group LLC
Via GlobeNewswire
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
From Altamira Therapeutics Ltd
Via GlobeNewswire
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
From Altamira Therapeutics Ltd
Via GlobeNewswire
Earnings Scheduled For April 10, 2024
Via Benzinga
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
From Altamira Therapeutics Ltd
Via GlobeNewswire
Nasdaq Turns Higher; Akanda Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Crude Oil Moves Higher; US New Home Sales Fall In February
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Altamira Therapeutics Stock Is Racing Higher
Via Benzinga
US Stocks Down; Chicago Fed National Activity Index Rises In February
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
From Altamira Therapeutics Ltd
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
From Altamira Therapeutics Ltd
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.